Reflections upon human cancer immune responsiveness to T cell-based therapy

Cancer Immunology, Immunotherapy

Volumn 61, Issue 6, 2012, Pages 761-770

  Wang, Ena ^a   Tomei, Sara ^a   Marincola, Francesco M ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Cancer vaccines; CIMT 2011; Immunoresponsiveness; Melanoma; Tumor immunotherapy

Indexed keywords

CANCER VACCINE; GAMMA INTERFERON; HLA ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; MELANOMA ANTIGEN 3; STAT1 PROTEIN; TUMOR ANTIGEN;

ANTIGEN RECOGNITION; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; GENOME; HUMAN; IMMUNE RESPONSE; LUNG CANCER; MELANOMA; METASTATIC MELANOMA; NEEDLE BIOPSY; NONHUMAN; NOTE; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR BIOPSY; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; TUMOR REGRESSION;

CANCER VACCINES; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ACTIVE; NEOPLASMS; T-LYMPHOCYTES;

EID: 84862326540     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1274-9     Document Type: Note

References (73)

1. Wolfel T, Klehmann E, Muller C, Schutt KH, Meyer zum Buschenfelde KH, Knuth A (1989) Lysis of human melanoma cells by autologous cytolytic T cell clones (1989) Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens. J Exp Med 170:797-810 (Pubitemid 19226665)
2. Kawakami Y, Zakut R, Topalian SL, Stotter H, Rosenberg SA (1992) Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas. J Immunol 148:638-643
3. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B et al (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643-1647 (Pubitemid 21917508)
4. Boon T, Cerottini J-C, Van den Eynde B, van der Bruggen P, Van Pel A (1994) Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12:337-365 (Pubitemid 24140418)
5. Rosenberg SA, Kawakami Y, Robbins PF, Wang R (1996) Identification of the genes encoding cancer antigens: implications for cancer immunotherapy. Adv Cancer Res 70(145-77):145-177
6. Rosenberg SA (1997) Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 18(4):175-182
7. Old LJ, Chen YT (1998) New paths in human cancer serology. J Exp Med 187(8):1163-1167 (Pubitemid 28189106)
8. Parmiani G, Castelli C, Dalerba P, Mortarini R, Rivoltini L, Marincola FM et al (2002) Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst 94(11):805-818 (Pubitemid 34705052)
9. van der Burg SH, Melief CJ (2011) Therapeutic vaccination against human papilloma virus induced malignancies. Curr Opin Immunol 23(2):252-257
10. Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10(9):909-915 (Pubitemid 39273730)
11. Mocellin S, Mandruzzato S, Bronte V, Marincola FM (2004) Correspondence 1: cancer vaccines: pessimism in check. Nat Med 10(12):1278-1279
12. Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J et al (2011) gp100 Peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 364(22):2119-2127
13. Bulloch MN, Elayan MM, Renfroe HR (2011) Sipuleucel-T: a therapeutic cancer vaccine for the treatment of castration- or hormone-refractory prostate cancer. Expert Rev Clin Pharmacol 4(6):685-692
14. Brichard VG, Lejeune D (2007) GSK's antigen-specific cancer immunotherapy programme: pilot results leading to phase III clinical development. Vaccine 25(Suppl 2):B61-B71 (Pubitemid 47488551)
15. Kammula US, Lee K-H, Riker A, Wang E, Ohnmacht GA, Rosenberg SA et al (1999) Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. J Immunol 163:6867-6879
16. Altman JD, Moss PA, Goulder PR, Barouch DH, McHeyzer-Williams MG, Bell JI et al (1996) Phenotypic analysis of antigen-specific T lymphocytes [published erratum appears in Science 1998 Jun 19;280(5371):1821] Science 274(5284):94-96 (Pubitemid 26332731)
17. Nielsen M-B, Monsurro' V, Miguelse S, Wang E, Perez-Diez A, Lee K-H et al (2000) Status of activation of circulating vaccine-elicited CD8+ T cells. J Immunol 165(4):2287-2296
18. Monsurro' V, Wang E, Yamano Y, Migueles SA, Panelli MC, Smith K et al (2004) Quiescent phenotype of tumor-specific CD8+ T cells following immunization. Blood 104(7):1970-1978
19. Lee K-H, Wang E, Nielsen M-B, Wunderlich J, Migueles S, Connors M et al (1999) Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol 163:6292-6300
20. Marincola FM, Wang E, Herlyn M, Seliger B, Ferrone S (2003) Tumors as elusive targets of T cell-based active immunotherapy. Trends Immunol 24(6):335-342
21. Monsurro' V, Wang E, Panelli MC, Nagorsen D, Jin P, Smith K et al (2003) Active-specific immunization against melanoma: is the problem at the receiving end? Sem Cancer Biol 13:473-480
22. Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS et al (1999) Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 5(6):677-685 (Pubitemid 29289432)
23. Critchley-Thorne RJ, Yan N, Nacu S, Weber J, Holmes SP, Lee PP (2007) Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med 4(5):e176
24. Critchley-Thorne RJ, Simons D, Yan N, Miyahira A, Dirbas F, Johnson D et al (2009) Impaired interferon signaling is a common immune defect in human cancer. Proc Natl Acad Sci USA 106(22):9010-9015
25. Mortarini R, Vegetti C, Molla A, Arienti F, Ravagnani F, Maurichi A et al (2009) Impaired STAT phosphorylation in T cells from melanoma patients in response to IL-2: association with clinical stage. Clin Cancer Res 15(12):4085-4094
26. Marincola FM, Rivoltini L, Salgaller ML, Player M, Rosenberg SA (1996) Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence for in vivo priming by tumor cells. J Immunother 19(4):266-277 (Pubitemid 26313518)
27. D'Souza S, Rimoldi D, Lienard D, Lejeune F, Cerottini JC, Romero P (1998) Circulating Melan-A/Mart-1 specific cytolytic T lymphocyte precursors in HLA-A2? melanoma patients have a memory phenotype. Int J Cancer 78(6):699-706 (Pubitemid 28530392)
28. Cormier JN, Salgaller ML, Prevette T, Rosenberg SA, Marincola FM (1996) Assessment of tumor specific immune reactivity in patients receiving immunization with the MART-1 melanoma antigen immunodominant peptide. ProcAmAss Cancer Res 37:476
29. Salgaller ML, Marincola FM, Cormier JN, Rosenberg SA (1996) Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res 56:4749-4757 (Pubitemid 26338080)
30. Kaech SM, Hemby S, Kersh E, Ahmed R (2002) Molecular and functional profiling of memory CD8 T cell differentiation. Cell 111:837-851 (Pubitemid 36106405)
31. Burnet FM (1970) The concept of immunological surveillance. Prog Exp Tumor Res 13:1-27
32. Marincola FM, Jaffe EM, Hicklin DJ, Ferrone S (2000) Escape of human solid tumors from T cell recognition: molecular mechanisms and functional significance. Adv Immunol 74:181-273
33. Mantovani A, Romero P, Palucka AK, Marincola FM (2008) Tumor immunity: effector response to tumor and the influence of the microenvironment. Lancet 371(9614):771-783
34. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM (2007) Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 370(9581):59-67 (Pubitemid 47017468)
35. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C et al (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795):1960-1964 (Pubitemid 44498003)
36. Ascierto ML, De Giorgi V, Liu Q, Bedognetti D, Murtas D, Chouchane L et al (2011) An immunologic portrait of cancer. J Transl Med 9:146
37. Garrido F, Cabrera T, Aptsiauri N (2010) "Hard" and "soft"lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy. Int J Cancer 127(2):249-256
38. Seliger B (2012) Novel insights into the molecular mechanisms of HLA class I abnormalities. Cancer Immunol Immunother 61(2):249-254
39. Poschke I, Mougiakakos D, Kiessling R (2011) Camouflage and sabotage: tumor escape from the immune system. Cancer Immunol Immunother 60(8):1161-1171
40. Dunn GP, Old LJ, Schreiber RD (2004) The three Es of cancer immunoediting. Annu Rev Immunol 22:329-360 (Pubitemid 38680426)
41. Wang E (2010) From the "delayed allergy reaction" to the "immunologic constant of rejection". In: Wang E, Marincola FM (eds) Immunologic signatures of rejection, 1st edn. Springer, New York, pp 3-8
42. Marincola FM (2007) In support of descriptive studies: relevance to translational research. J Transl Med 5:21
43. Wang E, Marincola FM (2008) Bottom up: a modular view of immunology. Immunity 29:9-11 (Pubitemid 351952466)
44. Wang E, Selleri S, Sabatino M, Monaco A, Pos Z, Stroncek DF et al (2008) Spontaneous and tumor-induced cancer rejection in humans. Exp Opin Biol Ther 8(3):337-349 (Pubitemid 351428421)
45. Wang E, Miller LD, Ohnmacht GA, Mocellin S, Petersen D, Zhao Y et al (2002) Prospective molecular profiling of subcutaneous melanoma metastases suggests classifiers of immune responsiveness. Cancer Res 62:3581-3586 (Pubitemid 34728828)
46. Panelli MC, Stashower M, Slade HB, Smith K, Norwood C, Abati A et al (2006) Sequential gene profiling of basal cell carcinomas treated with Imiquimod in a placebo-controlled study defines the requirements for tissue rejection. Genome Biol 8(1):R8
47. Weiss G, Grosh WW, Chianese-Bullock KA, Zhao Y, Liu H, Slingluff CL et al (2011) Molecular insights on the peripheral and intra-tumoral effects of systemic high dose rIL-2 (Aldesleukin) administration for the treatment of metastatic melanoma. Clin Cancer Res 17(23):7440-7450
48. Carretero R, Wang E, Rodriguez AI, Reinboth J, Ascierto ML, Engle AM et al (2011) Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes. Int J Cancer. (Epub ahead of print)
49. Mocellin S, Panelli MC, Wang E, Nagorsen D, Marincola FM (2002) The dual role of IL-10. Trends Immunol 24(1):36-43 (Pubitemid 35462111)
50. Wang E, Marincola FM (2000) A natural history of melanoma: serial gene expression analysis. Immunol Today 21(12):619-623 (Pubitemid 32044018)
51. Cormier JN, Hijazi YM, Abati A, Fetsch P, Bettinotti M, Steinberg SM et al (1998) Heterogeneous expression of melanoma-associated antigens (MAA) and HLA-A2 in metastatic melanoma in vivo. Int J Cancer 75:517-524 (Pubitemid 28094095)
52. Pockaj BA, Sherry RM, Wei JP, Yannelli JR, Carter CS, Leitman SF et al (1994) Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. Cancer 73:1731-1737
53. Mocellin S, Ohnmacht GA, Wang E, Marincola FM (2001) Kinetics of cytokine expression in melanoma metastases classifies immune responsiveness. Int J Cancer 93:236-242 (Pubitemid 32574280)
54. Ohnmacht GA, Wang E, Mocellin S, Abati A, Filie A, Fetsch PA et al (2001) Short term kinetics of tumor antigen expression in response to vaccination. J Immunol 167:1809-1820 (Pubitemid 32703186)
55. Wang E, Worschech A, Marincola FM (2008) The immunologic constant of rejection. Trends Immunol 29(6):256-262
56. Boon T, Coulie PG, van den Eynde BJ, Van Der BP (2006) Human T cell responses against melanoma. Annu Rev Immunol 24:175-208
57. Lander ES (1996) The new genomics: global view of biology. Science 274:536-539
58. Wang E, Marincola FM (2001) cDNA microarrays and the enigma of melanoma immune responsiveness. Cancer J Sci Am 7(1):16-23 (Pubitemid 32199099)
59. Wang E, Panelli MC, Monsurro' V, Marincola FM (2004) Gene expression profiling of anti-cancer immune responses. Curr Opin Mol Ther 6(3):288-295 (Pubitemid 38997129)
60. Wang E, Uccellini L, Marincola FM (2012) A genetic inference on cancer immune responsiveness. Oncoimmunology. In press
61. Gajewski TF (2010) Transcriptional profiling of melanoma as a potential predictive biomarker for response to immunotherapy. In Wang E, Marincola FM (eds) Signatures of rejection, 1st edn. Springer, New York, pp 229-238
62. Gajewski TF, Zha Y, Thurner B, Schuler G (2009) Association of gene expression profile in melanoma and survival to a dentritic cell-based vaccine. J Clin Oncol 27:A9002
63. Louahed J, Grusell O, Gaulis S, Coche T, Eggermont AM, Kruit W et al (2008) Expression of defined genes indentifed by pre-treatment tumor profiling: association with clinical response to GSK MAGE A-3 immunetherapeutic in metastatic melanoma patients. J Clin Oncol 26:A9045
64. Panelli MC, Wang E, Phan G, Puhlman M, Miller L, Ohnmacht GA et al (2002) Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. Genome Biol 3(7):RESEARCH0035
65. Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA (2001) Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 19(15):3477-3482 (Pubitemid 32730084)
66. Sarwal M, Chua MS, Kambham N, Hsieh SC, Satterwhite T, Masek M et al (2003) Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 349(2):125-138 (Pubitemid 36818782)
67. Salk J (1969) Immunological paradoxes: theoretical considerations in the rejection or retention of grafts, tumors, and normal tissue. Ann N Y Acad Sci 164(2):365-380
68. Spivey TL, Uccellini L, Ascierto ML, Zoppoli G, De Giorgi V, Delogu LG et al (2011) Gene expression profiling in acute allograft rejection: challenging the immunologic constant of rejection hypothesis. J Transl Med 9:174
69. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R et al (2005) Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353(25):2654-2666 (Pubitemid 41817714)
70. Gajewski TF, Louahed J, Brichard VG (2010) Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J 16(4):399-403
71. Sabatino M, Zhao Y, Voiculescu S, Monaco A, Robbins PF, Nickoloff BJ et al (2008) Conservation of a core of genetic alterations over a decade of recurrent melanoma supports the melanoma stem cell hypothesis. Cancer Res 68(1):222-231
72. Wang E, Voiculescu S, Le Poole IC, el Gamil M, Li X, Sabatino M et al (2006) Clonal persistence and evolution during a decade of recurrent melanoma. J Invest Dermatol 126(6):1372-1377 (Pubitemid 43997921)
73. Marincola FM (2011) The trouble with translational medicine. J Int Med 270(2):123-127